Last reviewed · How we verify
E coli Vaccine 4 Dose B (e-coli-vaccine-4-dose-b)
The E coli Vaccine 4 Dose B, developed by Pfizer Inc., is a marketed drug for preventing traveler's diarrhea caused by ETEC in travelers to areas where this disease is common. It is a vaccine that has undergone 1 trial and has 0 publications. The commercial significance of this drug is not specified. There are no pipeline developments mentioned. The mechanism of action is not provided. This drug is marketed for its ability to prevent a specific type of diarrhea.
At a glance
| Generic name | e-coli-vaccine-4-dose-b |
|---|---|
| Sponsor | Pfizer Inc. |
| Drug class | Not available |
| Target | Not available |
| Modality | Vaccine |
| Phase | FDA-approved |
Approved indications
- Traveler's Diarrhea
- Typhoid Fever
- Shigella
- Cholera
Common side effects
Drug interactions
- Warfarin
- Antacids
- Heparin
- Aspirin
- Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Corticosteroids
- Immunosuppressants
- Live vaccines
- Interferons
- Thalidomide
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- E coli Vaccine 4 Dose B CI brief — competitive landscape report
- E coli Vaccine 4 Dose B updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI